AWM
CUE icon

Accurate Wealth Management’s Cue Biopharma CUE Stock Holding History

Accurate Wealth Management’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-85
Closed -$7.6K – 510
2022
Q4 		$7.6K Buy
+85
New +$7.77K ﹤0.01% 928

Other funds holding CUE

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Accurate Wealth Management's CUE Position: Q1 2023 in Review

Accurate Wealth Management sold out of Cue Biopharma (CUE) in Q1 2023, closing a stake of 85 shares — an estimated $7.6K sold.

Accurate Wealth Management first reported a position in CUE in Q4 2022 and held it in 1 quarter. The position peaked at $7.6K in Q4 2022. 63 funds tracked by Wall St. Rank hold CUE as of Q1 2023.

  • Accurate Wealth Management reported no remaining Cue Biopharma position as of Q1 2023 after selling out during the quarter.
  • Accurate Wealth Management sold 85 Cue Biopharma shares in Q1 2023, an estimated $7.6K.
  • Accurate Wealth Management first reported a position in Cue Biopharma in Q4 2022 and held it in 1 quarter.
  • Accurate Wealth Management's Cue Biopharma position peaked at $7.6K in Q4 2022.
  • 63 funds tracked by Wall St. Rank held Cue Biopharma as of Q1 2023.

Based on Accurate Wealth Management's 13F filing for Q1 2023, filed 13 Apr 2023.